The CRISPR/Cas9-mediated KO and pharmacologic targeting of ZEB1 with honokiol reversed the mesenchymal gene expression and associated stem cell, invasion and metabolic changes of glioblastoma cells [20]. Here, ZEB1 is linked to glioblastoma.